Testing TRS005 for relapsed/refractory CD20-positive DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called TRS005 for people with a specific type of lymphoma (CD20-positive DLBCL) that has come back or not responded to at least two prior treatments. It is for those who cannot have a stem cell transplant and aims to see if the drug can shrink tumors and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have CD20-positive diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma).
- Your lymphoma must have returned or not responded after at least 2 previous treatments.
- You cannot be a candidate for a stem cell transplant using your own cells.
- You must have at least one tumor that can be measured (a lymph node bigger than 1.5 cm or a tumor outside the lymph nodes bigger than 1 cm).
- You must be in generally good health (able to do daily activities, with good organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TRS005 combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) for people who haven't yet been treated for a type of lymphoma called CD20-positive DLBCL. The goal is to see if adding TRS005 helps more people get better.
This trial tests an experimental drug called SCTB35 for people with relapsed or refractory B-cell non-Hodgkin lymphoma that is CD20-positive. It aims to find a safe dose and see how well it works.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This trial tests a new type of immune cell that targets two markers (CD19 and CD22) on lymphoma cells. It is for patients whose lymphoma has come back or not responded after at least two prior treatments.
Hear when a new CD20-positive Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.